Israel starts clinical trial of plasma-derived Covid drug

Physicians at Hadassah University Medical Center in Jerusalem report promising early results of a clinical study in which they are treating Covid-19 patients with immunoglobulin derived from the plasma of recovered patients found to have high levels of antibodies.

The serum is prepared by Rehovot-based biopharmaceutical company Kamada.

Three patients have already received the serum and are doing well, according to Dr. Yaron Ilan, chief of internal medicine at Hadassah University Medical Center. "The first patient demonstrated a rapid clinical benefit and went home after previously being in mod...